19-11041565-G-C
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001387283.1(SMARCA4):c.4520+5G>C variant causes a splice region, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_001387283.1 splice_region, intron
Scores
Clinical Significance
Conservation
Publications
- Coffin-Siris syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, Illumina
- intellectual disability, autosomal dominant 16Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
- rhabdoid tumor predisposition syndrome 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
- uterine corpus sarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- familial rhabdoid tumorInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| SMARCA4 | NM_001387283.1 | c.4520+5G>C | splice_region_variant, intron_variant | Intron 31 of 35 | ENST00000646693.2 | NP_001374212.1 | ||
| SMARCA4 | NM_003072.5 | c.4424+5G>C | splice_region_variant, intron_variant | Intron 30 of 34 | ENST00000344626.10 | NP_003063.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SMARCA4 | ENST00000646693.2 | c.4520+5G>C | splice_region_variant, intron_variant | Intron 31 of 35 | NM_001387283.1 | ENSP00000495368.1 | ||||
| SMARCA4 | ENST00000344626.10 | c.4424+5G>C | splice_region_variant, intron_variant | Intron 30 of 34 | 1 | NM_003072.5 | ENSP00000343896.4 | |||
| SMARCA4 | ENST00000643549.1 | c.4430+5G>C | splice_region_variant, intron_variant | Intron 30 of 34 | ENSP00000493975.1 | |||||
| SMARCA4 | ENST00000541122.6 | c.4334+5G>C | splice_region_variant, intron_variant | Intron 30 of 34 | 5 | ENSP00000445036.2 | ||||
| SMARCA4 | ENST00000643296.1 | c.4334+5G>C | splice_region_variant, intron_variant | Intron 29 of 33 | ENSP00000496635.1 | |||||
| SMARCA4 | ENST00000644737.1 | c.4334+5G>C | splice_region_variant, intron_variant | Intron 29 of 33 | ENSP00000495548.1 | |||||
| SMARCA4 | ENST00000589677.5 | c.4334+5G>C | splice_region_variant, intron_variant | Intron 30 of 34 | 5 | ENSP00000464778.1 | ||||
| SMARCA4 | ENST00000643995.1 | c.3845+5G>C | splice_region_variant, intron_variant | Intron 27 of 31 | ENSP00000496004.1 | |||||
| SMARCA4 | ENST00000644963.1 | c.3077+5G>C | splice_region_variant, intron_variant | Intron 23 of 27 | ENSP00000495599.1 | |||||
| SMARCA4 | ENST00000644065.1 | c.3059+5G>C | splice_region_variant, intron_variant | Intron 22 of 26 | ENSP00000493615.1 | |||||
| SMARCA4 | ENST00000642350.1 | c.2918+5G>C | splice_region_variant, intron_variant | Intron 22 of 26 | ENSP00000495355.1 | |||||
| SMARCA4 | ENST00000643857.1 | c.2786+5G>C | splice_region_variant, intron_variant | Intron 21 of 24 | ENSP00000494159.1 | |||||
| SMARCA4 | ENST00000538456.4 | c.590+5G>C | splice_region_variant, intron_variant | Intron 4 of 7 | 3 | ENSP00000495197.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:1
The c.4520+5G>C intronic variant results from a G to C substitution 5 nucleotides after coding exon 30 in the SMARCA4 gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at